Expression of Concern: Different Patterns of Akt and ERK Feedback Activation in Response to Rapamycin, Active-Site mTOR Inhibitors and Metformin in Pancreatic Cancer Cells (PLoS ONE (2013) 8:2 (e57289) DOI: 10.1371/journal.pone.0057289);Different Patterns of Akt and ERK Feedback Activation in Response to Rapamycin, Active-Site mTOR Inhibitors and Metformin in Pancreatic Cancer Cells

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Soares, Heloisa P ^a,b   Ni, Yang ^a,c   Kisfalvi, Krisztina ^a   Sinnett Smith, James ^a   Rozengurt, Enrique ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 (4 AMINO 1 ISOPROPYL 1H PYRAZOLO[3,4 D]PYRIMIDIN 3 YL) 1H INDOL 5 OL; INITIATION FACTOR 4E BINDING PROTEIN 1; INSULIN; KU 63794; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN C1; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; NEUROTENSIN; PROTEIN KINASE B; PROTEIN P70; PROTEIN S6; RAPAMYCIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL STIMULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RESPONSE; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEEDBACK SYSTEM; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; PANCREAS CANCER; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84874310577     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0292422     Document Type: Erratum

References (73)

1. Laplante M, Sabatini DM, (2012) mTOR signaling in growth control and disease. Cell 149: 274-293.
2. Ma XM, Blenis J, (2009) Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10: 307-318.
3. Garami A, Zwartkruis FJ, Nobukuni T, Joaquin M, Roccio M, et al. (2003) Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol Cell 11: 1457-1466.
4. Zhang Y, Gao X, Saucedo LJ, Ru B, Edgar BA, et al. (2003) Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5: 578-581.
5. Foster KG, Fingar DC, (2010) Mammalian Target of Rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem 285: 14071-14077.
6. Wullschleger S, Loewith R, Hall MN, (2006) TOR signaling in growth and metabolism. Cell 124: 471-484.
7. Inoki K, Guan KL, (2006) Complexity of the TOR signaling network. Trends Cell Biol 16: 206-212.
8. Taniguchi CM, Emanuelli B, Kahn CR, (2006) Critical nodes in signaling pathways: insights into insulin action. Nat Rev Mol Cell Biol 7: 85-96.
9. Zoncu R, Efeyan A, Sabatini DM, (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12: 21-35.
10. Kornmann M, Maruyama H, Bergmann U, Tangvoranuntakul P, Beger HG, et al. (1998) Enhanced expression of the insulin receptor substrate-2 docking protein in human pancreatic cancer. Cancer Res 58: 4250-4254.
11. Kolb S, Fritsch R, Saur D, Reichert M, Schmid RM, et al. (2007) HMGA1 controls transcription of insulin receptor to regulate cyclin D1 translation in pancreatic cancer cells. Cancer Res 67: 4679-4686.
12. Kwon J, Stephan S, Mukhopadhyay A, Muders MH, Dutta SK, et al. (2009) Insulin receptor substrate-2 mediated insulin-like growth factor-I receptor overexpression in pancreatic adenocarcinoma through protein kinase Cdelta. Cancer Res 69: 1350-1357.
13. Stoeltzing O, Liu W, Reinmuth N, Fan F, Parikh AA, et al. (2003) Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer. Am J Pathol 163: 1001-1011.
14. Dong X, Javle M, Hess KR, Shroff R, Abbruzzese JL, et al. (2010) Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. Gastroenterology 139: 464-473.
15. Feng Z (2010) p53 Regulation of the IGF-1/AKT/mTOR Pathways and the Endosomal Compartment. Cold Spring Harb Perspect Biol 2, a001057.
16. Kisfalvi K, Guha S, Rozengurt E, (2005) Neurotensin and EGF induce synergistic stimulation of DNA synthesis by increasing the duration of ERK signaling in ductal pancreatic cancer cells. J Cell Physiol 202: 880-890.
17. Kisfalvi K, Rey O, Young SH, Sinnett-Smith J, Rozengurt E, (2007) Insulin potentiates Ca2+ signaling and phosphatidylinositol 4,5-bisphosphate hydrolysis induced by Gq protein-coupled receptor agonists through an mTOR-dependent pathway. Endocrinology 148: 3246-3257.
18. Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E, (2009) Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res 69: 6539-6545.
19. Young SH, Rozengurt E, (2010) Crosstalk between insulin receptor and G protein-coupled receptor signaling systems leads to Ca(2+) oscillations in pancreatic cancer PANC-1 cells. Biochem Biophys Res Commun 401: 154-158.
20. Rozengurt E, Sinnett-Smith J, Kisfalvi K, (2010) Crosstalk between Insulin/Insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res 16: 2505-2511.
21. Asano T, Yao Y, Shin S, McCubrey J, Abbruzzese JL, et al. (2005) Insulin receptor substrate is a mediator of phosphoinositide 3-kinase activation in quiescent pancreatic cancer cells. Cancer Res 65: 9164-9168.
22. Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, et al. (2005) The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation. Biochem Biophys Res Commun 331: 295-302.
23. Pham NA, Schwock J, Iakovlev V, Pond G, Hedley DW, et al. (2008) Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic duct cell carcinogenesis. BMC Cancer 8: 43.
24. Ying H, Elpek KG, Vinjamoori A, Zimmerman SM, Chu GC, et al. (2011) PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-kB cytokine network. Cancer Discovery 1: 158-169.
25. Efeyan A, Sabatini DM, (2010) mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol 22: 169-176.
26. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, et al. (2004) Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431: 200-205.
27. Harrington LS, Findlay GM, Gray A, Tolkacheva T, Wigfield S, et al. (2004) The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J Cell Biol 166: 213-223.
28. Tzatsos A, Kandror KV, (2006) Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation. Mol Cell Biol 26: 63-76.
29. Tzatsos A, Tsichlis PN, (2007) Energy depletion inhibits phosphatidylinositol 3-kinase/Akt signaling and induces apoptosis via AMP-activated protein kinase-dependent phosphorylation of IRS-1 at Ser-794. J Biol Chem 282: 18069-18082.
30. Carracedo A, Pandolfi PP, (2008) The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27: 5527-5541.
31. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332: 1317-1322.
32. Yu Y, Yoon SO, Poulogiannis G, Yang Q, Ma XM, et al. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science 332: 1322-1326.
33. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508.
34. Lane HA, Breuleux M, (2009) Optimal targeting of the mTORC1 kinase in human cancer. Curr Opin Cell Biol 21: 219-229.
35. Easton JB, Kurmasheva RT, Houghton PJ, (2006) IRS-1: Auditing the effectiveness of mTOR inhibitors. Cancer Cell 9: 153-155.
36. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J, (2008) Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA 105: 17414-17419.
37. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, et al. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol 7: e38.
38. Garcia-Martinez JM, Moran J, Clarke RG, Gray A, Cosulich SC, et al. (2009) Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 421: 29-42.
39. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, et al. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284: 8023-8032.
40. Yu K, Toral-Barza L, Shi C, Zhang WG, Lucas J, et al. (2009) Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res 69: 6232-6240.
41. Sawyers CL, (2003) Will mTOR inhibitors make it as cancer drugs? Cancer Cell 4: 343-348.
42. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA, (2008) Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 11: 32-50.
43. Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, et al. (2009) Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 27: 193-198.
44. Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, et al. (2010) Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer 10: 368.
45. Liu Q, Chang JW, Wang J, Kang SA, Thoreen CC, et al. (2010) Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benz o[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J Med Chem 53: 7146-7155.
46. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, et al. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70: 288-298.
47. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD, (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305.
48. Bowker SL, Majumdar SR, Veugelers P, Johnson JA, (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29: 254-258.
49. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, et al. (2009) New users of metformin are at low risk of incident cancer. Diabetes Care 32: 1620-1625.
50. Chong CR, Chabner BA, (2009) Mysterious metformin. Oncologist 14: 1178-1181.
51. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F, (2010) Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 9: 1092-1099.
52. Landman GWD, Kleefstra N, van Hateren KJJ, Groenier KH, Gans ROB, et al. (2010) Metformin associated with lower cancer mortality in type 2 diabetes. Diabetes Care 33: 322-326.
53. DeCensi A, Puntoni M, Goodwin P, Cazzaniga M, Gennari A, et al. (2010) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res 3: 1451-1461.
54. Li D, Yeung SCJ, Hassan MM, Konopleva M, Abbruzzese JL, (2009) Anti-diabetic therapies affect risk of pancreatic cancer. Gastroenterology 137: 482-488.
55. Currie CJ, Poole CD, Gale EA, (2009) The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52: 1766-1777.
56. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, et al. (2011) Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 11: 20.
57. Hardie DG, (2007) AMP-activated protein kinase as a drug target. Annu Rev Pharmacol Toxicol 47: 185-210.
58. Inoki K, Zhu T, Guan KL, (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577-590.
59. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, et al. (2004) The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6: 91-99.
60. Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, et al. (2006) TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 126: 955-968.
61. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, Mery A, et al. (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30: 214-226.
62. Carriere A, Romeo Y, Acosta-Jaquez HA, Moreau J, Bonneil E, et al. (2011) ERK1/2 phosphorylate raptor to promote Ras-dependent activation of mTOR Complex 1 (mTORC1). J Biol Chem 286: 567-577.
63. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074.
64. Ryder NM, Guha S, Hines OJ, Reber HA, Rozengurt E, (2001) G protein-coupled receptor signaling in human ductal pancreatic cancer cells: Neurotensin responsiveness and mitogenic stimulation. J Cell Physiol 186: 53-64.
65. Guha S, Lunn JA, Santiskulvong C, Rozengurt E, (2003) Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1. Cancer Res 63: 2379-2387.
66. Liu Q, Kirubakaran S, Hur W, Niepel M, Westover K, et al. (2012) Kinome-wide selectivity profiling of ATP-competitive mammalian target of rapamycin (mTOR) inhibitors and characterization of their binding kinetics. J Biol Chem 287: 9742-9752.
67. Jamieson S, Flanagan JU, Kolekar S, Buchanan C, Kendall JD, et al. (2011) A drug targeting only p110 α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types. Biochem J 438: 53-62.
68. Sinnett-Smith J, Kisfalvi K, Kui R, Rozengurt E, (2012) Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: Dependence on glucose concentration and role of AMPK. Biochem Biophys Res Commun (in press).
69. Siegel R, Ward E, Brawley O, Jemal A, (2011) Cancer statistics, 2011. CACancer J Clin 61: 212-236.
70. Hoang B, Benavides A, Shi Y, Yang Y, Frost P, et al. (2012) The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance. J Biol Chem 287: 21796-21805.
71. Arslan AA, Helzlsouer KJ, Kooperberg C, Shu XO, Steplowski E, et al. (2010) Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium (PanScan). Arch Intern Med 170: 791-802.
72. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, et al. (2010) Diabetes and cancer: a consensus report. Diabetes Care 33: 1674-1685.
73. Ning J, Clemmons DR, (2010) AMP-Activated Protein Kinase Inhibits IGF-I Signaling and Protein Synthesis in Vascular Smooth Muscle Cells via Stimulation of Insulin Receptor Substrate 1 S794 and Tuberous Sclerosis 2 S1345 Phosphorylation. Mol Endocrinol 24: 1218-1229.